Mr. Macfarlane has spent 38 years in the Procter & Gamble Company, primarily in the International Divisions, starting in consumer products marketing and later in general management. During this period he has lived and worked abroad in Rome (66-71), Brussels (71-75), Toronto (75-81), Paris (86-91) and London (91-96 and 98 to present).

Mr. Macfarlane transferred to join the group that led P&G into the Pharmaceutical industry in 1978. In 1985 Mr. Macfarlane led the successful acquisition of the French pharmaceutical group, Nativelle, for P&G, and went on to serve as its President for six years in Paris. From this position Mr. Macfarlane also served as P&G's pharmaceutical executive responsible for Southern Europe (86-91). In 1991 he established the pharmaceutical Business Development role in Europe and relocated to London (91-96).

In 1996 Mr. Macfarlane returned to the US where he took over his current responsibility for all Alliance, Licensing and Acquisition activity of P&G in the expanded Health Care Global Business Unit (incorporating Pharmaceuticals, OTC medicines, Oral Care, Iams Pet Care, and Pur Water Treatment). While retaining this global responsibility, Mr. & Mrs. Macfarlane returned to London in 1998.

While in Paris, Mr. Macfarlane was active as a Board Member and Director of the American Chamber of Commerce in Paris (86-91). In London he was the founding Chairman of British American Business Inc's. EU Trade and Investment Policy Committee and now serves as the head of the Policy Group. He is a member of the Board and Executive Committee of BABi.

Dimitri F. Dimitriou, M.Sc.
Chairman

Mr. Dimitriou has 20 years experience in the pharmaceutical and biotech industry in business development, marketing, sales, finance and R&D and has been involved in over 100 industry collaborations. Mr. Dimitriou is a co-founder and CEO of ImmuPharma PLC, a drug discovery and development company listed in London (LSE:IMM), focusing on the treatment of serious medical conditions. He is also the founder and CEO of DyoDelta Biosciences Ltd, a company specialising in putting together corporate deals between pharma and biotech companies focusing on compounds and technologies. Prior to this, Mr. Dimitriou was Senior Director, Worldwide Business Development at GlaxoSmithKline and Bristol-Myers Squibb, where his responsibilities included worldwide transactions - licensing deals, alliances and collaborations with pharmaceutical and biotech companies. He moved to the biotech sector in 2001 as CEO of the London-based drug discovery company Xcellsyz. He begun his career as Product Manager in Marketing at Sandoz (now Novartis), and also spent 8 years in managerial positions in Procter & Gamble including overall responsibility for Sales and Marketing for the pharmaceutical business in Asia, R&D Finance, Clinical Development, and heading Medical Information prior to eventually becoming Business Development Manager-Europe, focusing on Licensing and Acquisitions of products and companies.

He received his first degree in Biochemistry from the University of London prior to graduating in Pathology from the Royal Postgraduate Medical School in London in 1984.

Sandrine Cailleteau is Head of Business Development & Licensing Operations of Laboratoires Fournier. Before joining Laboratoires Fournier in November 2002, she was Director Strategic Planning and Partnerships of Hesperion, a Clinical Development Organization, located in Switzerland, now part of Cerep. Prior to Hesperion, she spent 10 years with Sanofi, and then Sanofi-Synthelabo in different positions, the latest being Licensing Project Director at Paris headquarters. Her prior different positions at Sanofi included Manager Investor Relations, M&A and Strategic Planning Manager, where she was responsible for both acquisitions and divestitures, and then Public Affairs (where she spent 3 years in Washington DC, representing Sanofi with International Organizations and notably the World Bank).

She is graduated in Political Sciences from IEP Paris and holds an MBA from the French Chamber of Commerce of Paris (HEC-ISA).

Before joining Lilly in 1991, Andrew was in the academic department of psychiatry at Oxford University. At Lilly he has been involved in many aspects of drug development, with particular emphasis on Neuroscience compounds, and has led both clinical and preclinical research activities in UK, Belgium and Japan. He began his current assignment in July 2003, and is currently responsible for the European component of Lilly's global partnering function, focused on the scientific and technical assessment of external opportunities across all therapeutic areas.

Andrew has a degree in natural sciences from Cambridge University and in clinical medicine from Oxford University. He also holds a DM from Oxford University.

Sean Marett joined Lorantis in August 2003, as VP of Business Development; previously he worked for Evotec OAI where he oversaw the commercial and business development strategy as Chief Business Officer. In that role, he was responsible for leading the business development function and negotiating significant deals for the company. Prior to Evotec OAI, Sean worked for GSK, initially in global marketing in the UK before taking up a New Product Planning position in the US, where he was responsible for new product introductions into the US market place. Prior to GSK, Sean held a number of UK sales and marketing positions with pharmaceutical companies including Celltech and Wyeth. Sean holds an MBA from Manchester Business School and a BSc in Biochemistry from Kings College London.

Born in England, Andrew Barber earned a BSc. and Ph.D. in Neuroscience before taking up a position as a Scientific Assistant at the University of Munich, Germany in 1982. After joining the firm Merck KGaA in Darmstadt he worked in the CNS research department where he authored or co-authored numerous publications in peer-reviewed international science journals, and was the co-author of various patents in the fields of novel analgesics, opiates, new serotonergic and amino acid antagonists, and neuroprotectants. In 1998 he changed to Business Development where he has been supporting Merck Pharma goals through his activities in the licensing area. Since June 2002 he has been the person within Business Development at Darmstadt responsible for the area of High Potential Products, non-core projects with an emphasis on further development within the framework of partnerships. In 2000 he was awarded an MBA from Ashridge Management College.

Paolo Bessieres joined Sigma Tau in 1987 in the Business Development function and has been in charge of collaborations with particular focus on Asia/Pacific. He has been involved in numerous collaboration projects over the past 20 years and has finalised over 20 deals. His experience includes partnerships for Sigma Tau products in Japan, Korea, India, Taiwan, China, Hong Kong, The Philippines and Australia, developing an outstanding expertise of the business environment in these markets. He also pioneered the creation of joint ventures with other companies in China and India, also overseeing the alliance management. Prior to Sigma Tau, Dr Bessieres was working in the healthcare field in both hospitals and private pharmacies.

Dr Bessieres received his honours degree in Pharmacy in 1937 at the University of Rome, has been a member of many professional organisations as well as a speaker in international conferences.

Shin Kitaoka, B.Sc., MBA, London-based Japanese national and Japan expert, CEO of BioGemini Ltd., specialising in partnerships involving Asian partners. BioGemini provides complete coverage of all the Japanese companies, with senior contacts (>400), many at Board-level. Mr. Kitaoka was GlaxoSmithKline's Director of Business Development - Japan/Pacific, focusing on identifying licensing opportunities from Asia, establishing and maintaining relationships with Asian companies and their top management. Prior to Business Development, he was Head of Japan Liaison for Glaxo Wellcome R&D and has spent 25 years in SmithKline Beecham, Glaxo Wellcome and GSK.

Beatrice Leigh has over 24 years experience in the pharmaceutical industry both as a research scientist and as an R&D manager. She is an expert in collaborations involving platform technologies and was GlaxoSmithKline's Director of Operations for Technology Development, involved aiming to design and build to prototype level, new platform technologies to make R&D more efficient by reducing cost and cycle time. Projects were funded by GSK's internal VC fund and carried out in partnership with university start-ups and technology companies. Dr. Leigh had direct involvement in setting up two start-ups, fully funded by GSK and so has a good knowledge of the process. She was also responsible for two multi-million pound Technology Access Programmes in the US. In addition to general management of the department, Dr. Leigh was responsible for technical evaluation of new opportunities from external sources both academic and industrial. She has extensive networks worldwide encompassing the academic sector, R&D intensive industry, government funding agencies as well as the VC and Angel financial communities. She left GSK in 2004 to become involved in the biotech sector.

Dr. Leigh is a graduate biochemist and has worked as a researcher in the academic base, both in the US at Harvard Medical School and the UK for Cambridge University and the Medical Research Council, before moving to industry in 1980. For the last 15 years she has managed academic interactions for the SmithKline Beecham R&D scientists worldwide, managing a transnational team in the US and UK, to negotiate with universities with respect to collaborative research agreements and licences, drafting agreements, budgeting and project management of the larger multi-party collaborations. She was also involved in various UK government and EU schemes, including the Framework programmes, to stimulate interactions between industry and universities.

Dr. Leigh's present and past memberships include the Association of British Pharmaceutical Industry (ABPI) Academic Liaison Officers Working Party, past Chair of Confederation of British Industries (CBI) Intercompany Academic Relations Group and the CBI Technology and Innovation committee, the Association for University Research and Industrial Links (AURIL), University Companies ( UNICO), the Association of University Technology Managers (AUTM) in the US and the Council of the Engineering and Physical Sciences Research Council (EPSRC).

Val Tate has over 16 years' commercial experi­ence in start-up, private and publicly traded biotechnology companies, holding senior roles in Business Development and Commercial Management. This broad experience, encom­passing therapeutics, diagnostics and forensics, informs BioValue's top-level, strategic consultancy helping companies to define and articulate their corporate strategy to partners and investors. The BioValue approach has been particularly beneficial for early-stage companies seeking validating partnerships and seed investors. Dr Tate has also held several interim CEO roles for such young companies, where she was responsible for defining commercial strategy and moving organisations on to the next level in their evolution.

A background in medical communications for major international pharmaceutical companies was excellent grounding for her former role as Head of Investor Relations at London-based cancer company Antisoma, where she was a member of the IPO team on the European EASDAQ exchange and took part in subsequent fundraising rounds. She broadened this experience at NASDAQ and LSE-listed drug delivery company SkyePharma. Dr Tate was Director of Membership Services and Business Development at the UK BioIndustry Association and more recently has advised UK regional biotechnology networks on strategy and activities. Her extensive networks in both the biopharmaceutical and investor communities reach out into mainland Europe and the US.

She is a member and former Board Director of the UK Investor Relations Society.

With a PhD in biochemistry, Val had an earlier international academic career, holding research positions in Sweden (Uppsala), the US (Harvard) and the UK (Oxford). She has published widely in virology, gene structure, cloning and express­ion, and molecular genetics.